The VICTUS platform is described by the companies as the “first femtosecond laser capable of supporting cataract and corneal procedures on a single platform.” It is presently cleared for creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea and anterior capsulotomy during cataract surgery.
“Our pioneering research and development partnership with TPV has delivered innovation in laser surgery that allows us to offer a broader suite of ophthalmic surgical products and expand the global reach of this exciting new technology,” said John Barr, executive vice president and president, global surgical business for Bausch + Lomb, in the release. “Since signing a definitive agreement with an option to purchase TPV last September, the two organizations have made substantial technical and commercial progress in the field of advanced refractive and cataract technologies. This FDA clearance further strengthens our relationship with TPV and we look forward to bringing the power of the VICTUS femtosecond laser to the United States.”
Bausch + Lomb’s world headquarters is in Rochester, N.Y.
Related Articles on FDA Clearances:
Actuated Medical Receives FDA Clearance for Tubeclear System
Reflectance Medical Receives FDA Clearance for Oximeter
Proteus Digital Health Receives FDA Clearance for Ingestible Sensor
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.